AUSTIN, Texas / Aug 06, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA.
A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Last Trade: | US$127.78 |
Daily Change: | 0.65 0.51 |
Daily Volume: | 2,096,055 |
Market Cap: | US$15.800B |
September 16, 2024 September 14, 2024 September 08, 2024 August 08, 2024 July 26, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB